## SEC Form 4

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

| 1 |                          |           |  |  |  |  |  |
|---|--------------------------|-----------|--|--|--|--|--|
|   | OMB Number:              | 3235-0287 |  |  |  |  |  |
|   | Estimated average burden |           |  |  |  |  |  |
|   | hours per response:      | 0.5       |  |  |  |  |  |

| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | STATEMENT ( | OF CHANGES | IN BENEFICIAL | <b>OWNERSHIP</b> |
|--|-------------|------------|---------------|------------------|
|--|-------------|------------|---------------|------------------|

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| or Section So(n) of the investment Company Act or 1940 |         |            |   |  |                                 |                  |  |  |  |
|--|---------|------------|---|--|---------------------------------|------------------|--|--|--|
| 1. Name and Address of Reporting Person*               |         |            | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>Aldeyra Therapeutics, Inc. [ ALDX ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable) |                                 |                  |  |  |  |
| JOYCE MARTIN JOSEPH                                    |         | <u>ern</u> |   | X  | Director                        | 10% Owner        |  |  |  |
|  |         |            |   | -  | Officer (give title             | Other (specify   |  |  |  |
| (Last)   | (First) | (Middle)   | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/23/2022                            |  | below)                          | below)           |  |  |  |
| C/O ALDEYRA THERAPEUTICS, INC.                         |         |            | 06/23/2022  |  |                                 |                  |  |  |  |
| 131 HARTWELL AVENUE                                    |         |            |   |  |                                 |                  |  |  |  |
|  |         |            | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                  | 6. Indivi<br>Line)   | ing (Check Applicable           |                  |  |  |  |
| (Street)   |         |            |   | X  | Form filed by One Re            | porting Person   |  |  |  |
| LEXINGTON  | MA      | 02421      |   |  | Form filed by More th<br>Person | an One Reporting |  |  |  |
| (City)   | (State) | (Zip)      |   |  |                                 |                  |  |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |                                 |                                    | Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-----------------------------|---|--|---------------|---------------------------------|------------------------------------|---|---|
|                                 |  |   | Code                        | v | Amount   | (A) or<br>(D) | Price                           | Transaction(s)<br>(Instr. 3 and 4) |   | (1150. 4)   |
| Common Stock                    | 06/23/2022                                 |   | Р                           |   | 4,323  | Α             | <b>\$</b> 3.4755 <sup>(1)</sup> | 23,967                             | D   |   |

|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities) |  |   |   |   |  |   |   |  |  |  |  |
|--|--|--|---|---|---|--|---|---|--|--|--|--|
| 1. Title o<br>Derivati<br>Security<br>(Instr. 3) | /e Conversion  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code (Instr.<br>8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |

Date Exercisable Expiration Date v (D) Code (A) Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.475 to \$3.4756, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

#### **Remarks:**

/s/ Martin Joyce

Title

06/27/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Amount or Number

of Shares

Date